Effects of Urolithin A Supplementation on Glucose Metabolism in Healthy Adults 55 >= Years Old: A Randomized Triple-Masked Controlled Clinical Trial

Recruiting now · Not applicable · Has a placebo group

Conditions studied: Healthy Volunteer

In brief

Background: As people age, the cells in the pancreas that produce insulin begin to release less of this hormone, and levels of blood glucose (sugar) rise. This can lead to illnesses such as diabetes. Urolithin A (UA) is a natural nutritional supplement that may improve how the body controls blood glucose. Objective: To learn if UA improves levels of insulin and other hormones that help control blood glucose. Eligibility: People aged 55 years and older with a body mass index of 27 or higher. Design: Participants will have 6 clinic visits over 8 weeks. Participants will be screened. They will have a physical exam with blood and urine tests and a test of their heart function. UA gelcaps are taken by mouth every morning at home. Half of participants will take UA. The other half will take a placebo. The placebo looks like the study drug but does not contain any medicine. Participants will not know which they are taking. Participants will have tests during the study including: Oral glucose tolerance: Participants will drink a sweet liquid. Blood will be drawn at intervals over the next 3 hours. Continuous glucose monitor: A sensor with a needle that goes just under the skin will be placed on the upper arm. Participants will wear this sensor throughout the study. Exercise. Participants will walk on a treadmill while their heart rate, hearth rhythm, and blood pressure are monitored. They will walk in a hallway at normal and fast paces. Imaging scans of the thigh; scans of the brain are optional....

Key facts

Study ID

NCT06274749

Run by

National Institute on Aging (NIA)

People needed

180

Starts

2026-08-13

Expected to finish

2027-03-31

Last updated by the study team

2026-08-10

Who can join

Age: 55 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

• An individual who meets any of the following criteria will be excluded from participation in this study:
• History of diabetes requiring treatment with any glucose lowering drug(s).
• Fasting glucose >= 126 on screening visit.
• Is on treatment with an investigational drug or other intervention within 8 weeks of enrollment.
• Hospitalization within 12 months for myocardial infarction, coronary revascularization or bypass surgery or stroke.
• History of autoimmune disease, e.g., Hashimoto s thyroiditis, Myasthenia Gravis or Rheumatoid Arthritis.
• Uncontrolled thyroid disease.
• Chronic liver disease indicated by medical history or one of the liver enzymes greater than 2 times the normal range.
• History of chronic kidney disease or GFR <60 mL/min/1.73 m\^2.
• Anemia (defined as hemoglobin level <12 g/dl for men or < 11 g/dl for women).
• Poor venous access.
• Uncontrolled hypertension as judged by the Investigator.
• History of significant GI disease, e.g., IBS, Crohn s disease.
• Active cancer or has had treatment for cancer in the last 1 year.
• Medical condition requiring absolute and continuous need for long-term treatment with antibiotics, corticosteroids, immunosuppressors.
• Currently pregnant or a nursing mother due to possible changes in hormones and metabolism.
• History of, or laboratory evidence of HIV virus infection at Screening Visit.
• History of, or laboratory evidence of Hepatitis B or C at Screening Visit.
• Positive urine drug screen at Screening Visit (unless taking prescribed medication and at the discretion of the PI).
• Reports claustrophobia and/or is not eligible to have an MRI as per the MRI eligibility form.
• Weight >= 300 lbs (MRI scanner weight limit).
• Hip or knee replacement or other medical condition that prevents MRI research scans from being performed.
• Diagnosed with cognitive impairment that clearly prevents the participant from providing informed consent.
• Current smoker or tobacco use in the past year.
• History of substance abuse, including marijuana use in the past year.

Where it is running

• National Institute of Aging, Clinical Research Unit — Baltimore, Maryland, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.